FDA grants Breakthrough Device Designation for Apollo’s Orbera Balloon for NASH treatmentApollo Endosurgery has received a Breakthrough Device Designation from the FDA for the Orbera Intragastric Balloon, specifically for the...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure6 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity6 days ago